Craig Venter
John Craig Venter is an American scientist. He is known for leading one of the first draft sequences of the human genome and led the first team to transfect a cell with a synthetic chromosome. Venter founded Celera Genomics, the Institute for Genomic Research and the J. Craig Venter Institute. He was the co-founder of Human Longevity Inc. and Synthetic Genomics. He was listed on Time magazine's 2007 and 2008 Time 100 list of the most influential people in the world. In 2010, the British magazine New Statesman listed Craig Venter at 14th in the list of "The World's 50 Most Influential Figures 2010". In 2012, Venter was honored with the Dan David Prize for his contribution to genome research. He was elected to the American Philosophical Society in 2013. He is a member of the USA Science and Engineering Festival's advisory board.
Early life and education
John Craig Venter was born in Salt Lake City, Utah, the son of Elisabeth and John Venter. His family moved to Millbrae, California during his childhood. In his youth, he did not take his education seriously, preferring to spend his time on the water in boats or surfing. According to his biography, A Life Decoded, he was said never to be a terribly engaged student, having Cs and Ds on his eighth-grade report cards. Venter considered that his behavior in his adolescence was indicative of attention deficit hyperactivity disorder, and later found ADHD-linked genetic variants in his own DNA. He graduated from Mills High School. His father died suddenly at age 59 from cardiac arrest, giving him a lifelong awareness of his own mortality. He quotes a saying: "If you want immortality, do something meaningful with your life."Although he opposed the Vietnam War, Venter was drafted and enlisted in the United States Navy where he worked as a hospital corpsman in the intensive-care ward of a field hospital. He served from 1967 to 1968 at the Naval Support Activity Danang in Vietnam. While in Vietnam, he attempted suicide by swimming out to sea, but changed his mind more than a mile out.
Being confronted with severely injured and dying marines on a daily basis instilled in him a desire to study medicine, although he later switched to biomedical research.
Venter began his college education in 1969 at a community college, College of San Mateo in California, and later transferred to the University of California, San Diego, where he studied under biochemist Nathan O. Kaplan. He received a Bachelor of Science in biochemistry in 1972 and a Doctor of Philosophy in physiology and pharmacology in 1975 from UCSD.
Career
After working as an associate professor, and later as full professor, at the State University of New York at Buffalo, he joined the National Institutes of Health in 1984.EST controversy
While an employee of the NIH, Venter learned how to identify mRNA and began to learn more about those expressed in the human brain. The short cDNA sequence fragments Venter discovered by automated DNA sequencing, he named expressed sequence tags, or ESTs. The NIH Office of Technology Transfer decided to file a patent on the ESTs discovered by Venter, patenting the genes identified based on studies of mRNA expression in the human brain. When Venter disclosed the NIH strategy during a Congressional hearing, a firestorm of controversy erupted. The NIH later stopped the effort and abandoned the patent applications it had filed, following public outcry.Human Genome Project
Venter was passionate about the power of genomics to transform healthcare radically. Venter believed that whole genome shotgun sequencing was the fastest and most effective way to get useful human genome data. However, the method was rejected by the Human Genome Project, since some geneticists felt it would not be accurate enough for a genome as complicated as that of humans, that it would be logistically more difficult, and that it would cost significantly more.Venter viewed the slow pace of progress in the Human Genome Project as an opportunity to continue his interest in trying his shotgun sequencing method to speed up human genome sequencing, so he sought funding from the private sector to start Celera Genomics. The company planned to profit from their work by creating genomic data to which users could subscribe for a fee. The goal consequently put pressure on the public genome program and spurred several groups to redouble their efforts to produce the full sequence. Venter's effort won him renown as he and his team at Celera Corporation shared credit for sequencing the first draft human genome with the publicly funded Human Genome Project.
In 2000, Venter and Francis Collins of the National Institutes of Health and U.S. Public Genome Project jointly made the announcement of the mapping of the human genome, a full three years ahead of the expected end of the Public Genome Program. The announcement was made along with U.S. President Bill Clinton, and UK Prime Minister Tony Blair. Venter and Collins thus shared an award for "Biography of the Year" from A&E Network.
On February 15, 2001, the Human Genome Project consortium published the first Human Genome in the journal Nature, followed one day later by a Celera publication in Science. Despite some claims that shotgun sequencing was in some ways less accurate than the clone-by-clone method chosen by the Human Genome Project, the technique became widely accepted by the scientific community.
Venter was fired by Celera in early 2002. According to his biography, Venter was fired because of a conflict with the main investor, Tony White, specifically barring him from attending the White House ceremony celebrating the achievement of sequencing the human genome.
Global Ocean Sampling Expedition
The Global Ocean Sampling Expedition is an ocean exploration genome project with the goal of assessing the genetic diversity in marine microbial communities and to understand their role in nature's fundamental processes. Begun as a Sargasso Sea pilot sampling project in August 2003, the full Expedition was announced by Venter on March 4, 2004. The project, which used Venter's personal yacht, Sorcerer II, started in Halifax, Canada, circumnavigated the globe and returned to the U.S. in January 2006.Synthetic Genomics
In June 2005, Venter co-founded Synthetic Genomics, a firm dedicated to using modified microorganisms to produce clean fuels and biochemicals. In July 2009, ExxonMobil announced a $600 million collaboration with Synthetic Genomics to research and develop next-generation biofuels.Venter continues to work on the creation of engineered diatomic microalgae for the production of biofuels.
Venter is seeking to patent the first partially synthetic species possibly to be named Mycoplasma laboratorium. There is speculation that this line of research could lead to producing bacteria that have been engineered to perform specific reactions, for example, produce fuels, make medicines, combat global warming, and so on.
In May 2010, a team of scientists led by Venter became the first to create successfully what was described as "synthetic life". This was done by synthesizing a very long DNA molecule containing an entire bacterium genome, and introducing this into another cell, analogous to the accomplishment of Eckard Wimmer's group, who synthesized and ligated an RNA virus genome and "booted" it in cell lysate. The single-celled organism contains four "watermarks"
written into its DNA to identify it as synthetic and to help trace its descendants. The watermarks include
- Code table for entire alphabet with punctuations
- Names of 46 contributing scientists
- Three quotations
- The secret email address for the cell.
This stripped-down, fast reproducing cell is expected to be a valuable tool for researchers in the field.
In August 2018, Venter retired as chairman of the board, saying he wanted to focus on his work at the J. Craig Venter Institute. He will remain as a scientific advisor to the board.
J. Craig Venter Institute
In 2006 Venter founded the J. Craig Venter Institute, a nonprofit which conducts research in synthetic biology. It has facilities in La Jolla and in Rockville, Maryland and employs over 200 people.In April 2022 Venter sold the La Jolla JCVI facility to the University of California, San Diego for $25 million. Venter will continue to lead a separate nonprofit research group, also known as the J. Craig Venter Institute, and stressed that he is not retiring. The Venter Institute has out grown its current building with multiple new facility hires and will be moving into new space in 2025.
Individual human genome
On September 4, 2007, a team led by Sam Levy published one of the first genomes of an individual human—Venter's own DNA sequence. Some of the sequences in Venter's genome are associated with wet earwax, increased risk of antisocial behavior, Alzheimer's and cardiovascular diseases.The Human Reference Genome Browser is a web application for the navigation and analysis of Venter's recently published genome. The HuRef database consists of approximately 32 million DNA reads sequenced using microfluidic Sanger sequencing, assembled into 4,528 scaffolds and 4.1 million DNA variations identified by genome analysis. These variants include single-nucleotide polymorphisms, block substitutions, short and large indels, and structural variations like insertions, deletions, inversions and copy number changes.
The browser enables scientists to navigate the HuRef genome assembly and sequence variations, and to compare it with the NCBI human build 36 assembly in the context of the NCBI and Ensembl annotations. The browser provides a comparative view between NCBI and HuRef consensus sequences, the sequence multi-alignment of the HuRef assembly, Ensembl and dbSNP annotations, HuRef variants, and the underlying variant evidence and functional analysis. The interface also represents the haplotype blocks from which diploid genome sequence can be inferred and the relation of variants to gene annotations. The display of variants and gene annotations are linked to external public resources including dbSNP, Ensembl, Online Mendelian Inheritance in Man and Gene Ontology.
Users can search the HuRef genome using HUGO gene names, Ensembl and dbSNP identifiers, HuRef contig or scaffold locations, or NCBI chromosome locations. Users can then easily and quickly browse any genomic region via the simple and intuitive pan and zoom controls; furthermore, data relevant to specific loci can be exported for further analysis.